(May 2, 2018, 9:43 AM EDT) -- ALEXANDRIA, Va. — A patented method of administering the peptide drug terlipressin as a continuous infusion to ascites patients on an outpatient basis is both anticipated and rendered obvious by prior art, a petitioner told the Patent Trial and Appeal Board April 27 (Mallinckrodt Pharmaceuticals Ireland Limited v. Biovie Inc., No. IPR2018-00974, PTAB)....